Clinical applications of liquid biopsy at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

72 organizations at ISLB 2026 present work in clinical applications, led by universities and research institutes. Between them they bring 133 presentations to the program. Most represented: National and Kapodistrian University of Athens, University of Naples Federico II and Princess Margaret Cancer Centre. As of Oct 16, 2026.

All 160 organizations at ISLB 2026 →

Showing 1–8 of 72 organizations

Organization	ISLB 2026 Attendance
National and Kapodistrian University of Athens Athens, Greece
uoa.gr Universities & research institutes Public university in Athens, Greece, with schools of medicine and science.	Talk Sun Nov 8 3:45pm–5:15pm Part of Awards Lecture The Evolving Landscape of CTCs in Precision Oncology: A Marathon Race Worth Running Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Ultra-sensitive Detection of BRAF V600E in Plasma cfDNA of Early-stage Melanoma patients based on PD UV-ME ddPCR Poster Part of Poster sessions Droplet Digital PCR Analysis in Size-based Enriched Circulating Tumor Cells Reveals Unique ESR1 Subclonal Heterogeneity Missing in Plasma Cell-free DNA New analytes Poster Part of Poster sessions A Multi Cancer Basket Trial Evaluating Overexpression of PD-L1 mRNA in CTCs as a Predictive Biomarker for Response to Immunotherapy Clinical use · New analytes Poster Part of Poster sessions Liquid Biopsy EGFR Testing: Real-world Multicenter Experience in Greece Clinical use
University of Naples Federico II Naples, Italy
unina.it Universities & research institutes Public university in Naples, Italy, with a school of medicine and a teaching hospital.	Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Identifying Educational Needs to Support Personalized Medicine Approaches in Cancer (SPARC): Preliminary Results from the Work Package 6 Survey Collaborators: Universidad Politécnica de Madrid Industry Sun Nov 8 8:15am–9:15am Part of Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors From Diagnosis to Disease Monitoring: The Expanding Role of Liquid Biopsy Across Solid Tumours Industry hosted by AstraZeneca and Thermo Fisher Scientific Clinical use Industry Sun Nov 8 8:15am–9:15am Part of Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors Panel Discussion and Q&A Industry hosted by AstraZeneca and Thermo Fisher Scientific Clinical use Session Sun Nov 8 9:30am–11:00am Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures New analytes Talk Sun Nov 8 9:30am–11:00am Part of Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures Proteomics in Liquid Biopsy: The Future is Here? New analytes Industry Sun Nov 8 12:15pm–1:15pm Part of ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Opening and Introduction Industry hosted by Menarini Stemline Clinical use · Pre-analytics Industry Sun Nov 8 12:15pm–1:15pm Part of ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Clinical Cases Panel Discussion and Q&A Industry hosted by Menarini Stemline Clinical use · Pre-analytics Session Sun Nov 8 3:45pm–5:15pm Awards Lecture Talk Sun Nov 8 5:30pm–6:30pm Part of Young Career Session The Evolving Landscape of Next-generation Sequencing in Liquid Biopsy Industry Mon Nov 9 8:00am–9:00am Part of From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Welcome, Framing, and Objectives Industry hosted by Guardant Health Clinical use · ctDNA & MRD Industry Mon Nov 9 8:00am–9:00am Part of From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Panel Discussion & Live Q&A: What Makes a Longitudinal Liquid-Biopsy Result Actionable? Industry hosted by Guardant Health Clinical use · ctDNA & MRD Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Identifying Educational Needs to Support Personalized Medicine Approaches in Cancer (SPARC): Preliminary Results from the Work Package 6 Survey Poster Part of Poster sessions Technical Feasibility of a Digital Solid PCR Platform Multiplexing ESR1 Activating Mutation in Real-world Liquid Biopsy Samples ctDNA & MRD · New analytes Collaborators: QIAGEN
Princess Margaret Cancer Centre Toronto, Canada
uhn.ca Hospitals & cancer centres Cancer centre of University Health Network in Toronto, for cancer care, research and education.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Session Sun Nov 8 1:30pm–3:00pm Tumor Type Related Clinical use Talk Sun Nov 8 1:30pm–3:00pm Part of Tumor Type Related Multimodal Assays in HN/Perspectives from Radiation Oncology Clinical use Talk Sun Nov 8 3:45pm–5:15pm Part of Awards Lecture One Drop at a Time – Integrating Liquid Biopsy into Routine Practice Poster Part of Poster sessions Cell-free DNA Hydroxymethylation Profiling in Treatment-naive and Relapsed SCLC ctDNA & MRD Poster Part of Poster sessions Bronchoalveolar Lavage to Accelerate Time to Molecular Diagnosis in Early-stage Lung Cancer Pre-analytics · Clinical use
CIMA University of Navarra Pamplona, Spain
cima.cun.es Universities & research institutes Applied medical research centre of the University of Navarra, with a solid tumours programme.	Talk Sat Nov 7 9:45am–11:15am Part of Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches Multimodal Liquid Biopsy in SCLC New analytes Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Session Sat Nov 7 4:00pm–5:30pm Workshop Biological Fluids: Pre-analytical Issues Pre-analytics Poster Part of Poster sessions Novel Cytokine-based Liquid Biopsy Biomarkers Related to Response and Survival in SCLC Patients Treated with Chemoimmunotherapy Clinical use · New analytes
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) Madrid, Spain
imas12.es Universities & research institutes Health research institute of the 12 de Octubre University Hospital in Madrid.	Poster Part of Poster sessions "HER2 in Plasma Small Extracellular Vesicles for Monitoring Response to Trastuzumab Deruxtecan in Advanced Breast Cancer" New analytes · Clinical use Poster Part of Poster sessions Influence of Macrophage Polarization on Tumor Hybrid Cell Formation in Different Co-culture Models with Bladder Cancer Cell Lines New analytes Poster Part of Poster sessions Peripheral Immune Profiling by Multiparametric Flow Cytometry in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Deruxtecan Clinical use · New analytes Collaborators: Hospital Universitario 12 de Octubre
IRCCS Ospedale Policlinico San Martino Genoa, Italy
ospedalesanmartino.it Hospitals & cancer centres Public research hospital in Genoa and teaching hospital of the University of Genoa.	Poster Part of Poster sessions Clonal Hematopoiesis in Early Breast Cancer: A Pilot Study on Treatment Toxicity and Clinical Outcomes Clinical use Collaborators: Fondazione Edo ed Elvo Tempia Poster Part of Poster sessions Plasma and Pleural Effusion Profiling Reveals Histotype-related Immune Patterns in Pleural Mesothelioma Clinical use · Pre-analytics Poster Part of Poster sessions Role of Soluble TIM3 in Developing Acquired Resistance in Metastatic Non-small-cell Lung Cancer Patients Undergoing First-line Immune Checkpoint Inhibitor-based Therapy Clinical use · New analytes
IRST Dino Amadori Meldola, Italy
irst.emr.it Hospitals & cancer centres Cancer hospital and research institute in Meldola, in Italy's Romagna area.	Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Molecular Profiling of Bile-derived DNA: New Perspectives for the Diagnosis and Management of Biliopancreatic Tumors Poster Part of Poster sessions Longitudinal ctDNA Profiling Reveals Molecular Evolution and Resistance Mechanisms in BRAFV600E-mutant Metastatic Colorectal Cancer ctDNA & MRD · Clinical use Poster Part of Poster sessions Plasma and Tissue Assessment of Homologous Recombination Deficiency-related Genomic Instability in Prostate Cancer Clinical use · ctDNA & MRD
Ohio State University Columbus, OH
osu.edu Universities & research institutes Public research university in Columbus, Ohio, with a college of medicine and a comprehensive cancer center.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Talk Sun Nov 8 1:30pm–3:00pm Part of Tumor Type Related MRD and Hematologic Malignancies Clinical use Talk Sun Nov 8 5:30pm–6:30pm Part of Young Career Session Summary of ISLB YC 2026 Activities